# Evaluation of Apricoxib (Selective Cyclooxygenase 2 Inhibition) in Modulating T Regulatory Cells of Patients With Early Stage Non-small Cell Lung Cancer

> **NCT01532362** · NA · TERMINATED · sponsor: **Jonsson Comprehensive Cancer Center** · enrollment: 1 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Apricoxib

## Key facts

- **NCT ID:** NCT01532362
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-11
- **Primary completion:** 2012-05
- **Final completion:** 2012-05
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Drug sponsor stopped drug manufacture due to toxicity issues from other studies
- **Last updated:** 2020-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01532362

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01532362, "Evaluation of Apricoxib (Selective Cyclooxygenase 2 Inhibition) in Modulating T Regulatory Cells of Patients With Early Stage Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01532362. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*